Davido Watson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Polar Capital Holdings Plc increased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 126.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,053,875 shares of the company’s stock after acquiring an additional 588,875 shares during the quarter. […]

Covestor Ltd raised its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 564.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 797 shares of the company’s stock after purchasing an additional 677 shares during the period. Covestor Ltd’s holdings in Apellis […]

Wynnefield Capital Inc. purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company’s stock, valued at approximately $380,000. Apellis Pharmaceuticals comprises 0.2% of Wynnefield […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “outperform” rating reiterated by Robert W. Baird in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $81.00 price target on the stock. Robert W. Baird’s target price points to a potential upside of 21.68% from the stock’s previous close. […]

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) gapped down before the market opened on Tuesday following insider selling activity. The stock had previously closed at $65.45, but opened at $63.81. Apellis Pharmaceuticals shares last traded at $63.90, with a volume of 195,943 shares changing hands. Specifically, CAO James George Chopas sold 864 […]